

## Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival

Anna E. Coghill<sup>1,2</sup>, Polly A. Newcomb<sup>1,2</sup>, Elizabeth M. Poole<sup>1,3,4</sup>, Carolyn M. Hutter<sup>1</sup>, Karen W. Makar<sup>1</sup>, Dave Duggan<sup>5</sup>, John D. Potter<sup>1,2,6</sup>, and Cornelia M. Ulrich<sup>1,2,7</sup>

### Abstract

**Purpose:** Prognosis of patients with colorectal cancer (CRC) is associated with systemic inflammation, and anti-inflammatory drugs can reduce both CRC incidence and mortality. Genetic variation in proinflammatory pathways can affect an individual's CRC risk. However, few studies have investigated the prognostic importance of this genetic variation in CRC patients.

**Experimental Design:** We investigated the association between CRC survival and genetic variation in proinflammatory pathways among patients from the Puget Sound Surveillance Epidemiology and End Results registry. Single-nucleotide polymorphisms were genotyped in five genes (*PTGS-1*, *PTGS-2*, *MRP4*, *NFκB*, and *IκBκβ*). Vital status was ascertained through linkage to the National Death Index. Cox proportional hazards regression was used to calculate HRs and 95% confidence intervals (CI). The false discovery rate method of Benjamini and Hochberg was applied to address multiple testing.

**Results:** Four *PTGS-1* variants were associated with CRC survival. One, G>A intron 9 (rs1213266), was associated with approximately 50% lower CRC mortality (HR<sub>AA/AG vs. GG</sub> = 0.48; 95% CI, 0.25–0.93). Three variants, including L237M, resulted in significantly elevated CRC mortality risk, with HRs ranging from approximately 1.5 to 2.0. Two variants in *IκBκβ*, including R526Q, were significantly associated with CRC survival. Correction for multiple testing indicated that variants in both *PTGS-1* and *IκBκβ* are reproducibly associated with CRC survival.

**Conclusion:** Our findings suggest that genetic variation in proinflammatory pathways may be important for CRC prognosis. This investigation represents one of the first descriptions of the relationship between inherited polymorphisms and mortality in CRC patients and provides a starting point for further research. *Clin Cancer Res*; 17(22); 7139–47. ©2011 AACR.

### Introduction

Inflammation has consistently been associated with colorectal cancer (CRC) development and prognosis in clinic and population studies (1, 2). The role of inflammation in prognosis may be mediated through influences on pro-

cesses crucial for tumor progression, including metastasis and invasion (3–5). Medications that inhibit inflammation such as nonsteroidal anti-inflammatory drugs (NSAID), which interact with the prostaglandin synthesis pathway, decrease the risk of colorectal neoplasia (6–8). Consistent with inflammation's role not only in cancer development but also cancer progression, NSAIDs have also been associated in large, population-based studies with improved survival of patients with CRC (9–11).

The prostaglandin synthesis pathway is critical for regulation of inflammatory processes and plays a well-defined role in colorectal carcinogenesis (12, 13). Prostaglandin H synthases (COX-1 and COX-2) are pivotal enzymes in this pathway (14, 15); upregulation of prostaglandins results in cellular proliferation, angiogenesis, and increased cellular motility (16–18). The NFκB pathway represents another important proinflammatory pathway associated with CRC; NFκB is a transcription factor with multiple targets involved in inflammatory signaling and carcinogenesis, including prostaglandin synthases (19–22). The NFκB transcription factor plays a role not only in regulating cellular growth signals but also in regulating apoptosis and the survival of cancer cell populations (23, 24).

**Authors' Affiliations:** <sup>1</sup>Fred Hutchinson Cancer Research Center; <sup>2</sup>Department of Epidemiology, University of Washington, Seattle, Washington; <sup>3</sup>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; <sup>4</sup>Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; <sup>5</sup>Translational Genomics Research Institute, Phoenix, Arizona; <sup>6</sup>Center for Public Health Research, Massey University, Wellington, New Zealand; and <sup>7</sup>National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

**Corresponding Author:** Cornelia M. Ulrich, National Center for Tumor Diseases, Division of Preventive Oncology, German Cancer Research Center, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. E-mail: [nulrich@fhcrc.org](mailto:nulrich@fhcrc.org) or [neli.ulrich@nct-heidelberg.de](mailto:neli.ulrich@nct-heidelberg.de) and Polly A. Newcomb. E-mail: [pnewcomb@fhcrc.org](mailto:pnewcomb@fhcrc.org)

doi: 10.1158/1078-0432.CCR-11-1134

©2011 American Association for Cancer Research.

### Translational Relevance

The presence of common genetic variation can refine prediction of patient outcome for colorectal cancer (CRC) and help guide the management and risk assessment for individual patients. This study suggests that inflammatory pathway-associated genetic variation may possibly be useful for improving outcome prediction for CRC patients. These results improve our understanding of colorectal cancer progression, confirming that key cellular pathways involved in CRC incidence also play a role in disease progression. Identified genes provide a good starting point for further research and potential targets for CRC therapy, including pharmacogenetic research on COX inhibitors.

A study conducted in a Spanish population (25) investigated variation in 2 *PTGS-2* (*COX-2*) single-nucleotide polymorphisms (SNP; -765 G>C and 3618 A>G) among 284 patients with CRC in relation to tumor characteristics and disease prognosis. 3618 A>G was found to be a prognostic indicator for patients with CRC, with carriers of the variant allele experiencing approximately 60% improved survival compared with wild-type patients. To our knowledge, this has been the only population study to date examining polymorphisms in genes involved in the prostaglandin synthesis pathway in relation to CRC survival. However, multiple studies have noted that variation in genes encoding both prostaglandin synthases and the NFκB transcription factor is associated with CRC risk (26–29). We therefore hypothesized that variation in these important inflammation-associated genes would affect the survival of patients with CRC.

We examined SNPs in genes involved in both the prostaglandin synthesis pathway (*PTGS1* = *COX-1*, *PTGS2* = *COX-2*, *MRP4*) and the NFκB pathway (*NFκB*, *IκBKβ*) in relation to CRC survival among patients identified from the population-based Seattle Colon Cancer Family Registry. This investigation represents one of the first descriptions of the relationship between inherited genetic polymorphisms and survival after a diagnosis of CRC.

### Materials and Methods

#### Study population

The Colon Cancer Family Registry (Colon CFR) is a 6-site international collaboration established to investigate the genetic epidemiology of CRC. This report describes the Seattle Colon CFR, where patients with incident, invasive CRC occurring from 1997 to 2002 from 3 counties in Western Washington State were ascertained from the population-based Puget Sound Surveillance Epidemiology and End Results (SEER) Registry (30).

Patients with CRC from the Seattle Colon CFR who were genotyped as part of a Colon CFR-wide study of candidate

SNPs were included in our survival analysis (31). No patients reported multiple primary tumors. The parent study used a case/unaffected sibling control design, selecting CRC cases from each Colon CFR study site who had unaffected siblings also enrolled in the Colon CFR.

#### SNP selection and genotyping

Selection of tagSNPs and SNP genotyping methods for the parent study have been published previously (31). Briefly, tagSNPs for *PTGS-1*, *PTGS-2*, *MRP4*, *NFκB*, and *IκBKβ* were selected using Haploview Tagger and the following criteria: minor allele frequency (MAF) more than 5%, pairwise  $r^2$  of more than 0.95, and distance from closest SNP of more than 60 bps. The 5' and 3' untranslated regions (UTR) for each gene were extended to include the most up- or downstream SNP within the linkage disequilibrium (LD) block (~10 kb upstream and 5 kb downstream). In regions of no or low LD, SNPs with an MAF more than 5% at a density of approximately 1 per kb were selected from either HapMap or dbSNP.

We investigated the following tagSNPs: 17 in *PTGS-1*, 8 in *PTGS-2*, 41 in *NFκB*, 9 in *IκBKβ*, and 62 in *MRP4*. SNPs were genotyped on the Illumina platform in the laboratory of Dr. Duggan at Translational Genomics Research Institute (Phoenix, AZ). SNPs were excluded on the basis of the following criteria: GenTrain score of <0.4, 10% GC score of <0.25, ABT Dev of >0.1239, call rate of <0.95, or more than 2 P-P-C errors. Interplate and intraplate replicates were included, and SNPs were excluded from the analysis if there were more than 2 errors on the replicate genotypes. In addition, genotype data from 30 CEPH trios (Coriell Cell Repository) were used to confirm reliability and reproducibility of the genotyping. SNPs were excluded from the analysis if more than 3 genotypes were discovered to be discordant in comparison with the genotype from the International HapMap Project.

#### Outcome assessment

Vital status and date and cause of death were ascertained for all cases through linkage to the National Death Index (NDI) records; causes of death were classified using ICD10 codes. The NDI identifies known deaths throughout the United States with a high degree of sensitivity, validity, and completeness (32, 33). The primary outcome of interest was mortality from CRC, assessed from underlying cause of death obtained from the NDI. Time to CRC mortality was evaluated from SEER-reported date of CRC diagnosis and NDI-recorded date of death. Patients alive at the time of their last known vital assessment were censored at that date, with the most recent vital status linkage occurring December 31, 2009. Patients dying of causes other than CRC were censored at their recorded date of death.

Tumor characteristics at the time of diagnosis, including stage and subsite, were obtained from Surveillance Epidemiology and End Results reports. Advanced disease was defined as CRC with distant metastasis ( $n = 61$ ); nonadvanced disease included localized and regional stage disease ( $n = 362$ ). Subsite of disease was categorized using ICD10

codes: proximal (C18.0-C18.5); distal (C18.6-18.7); and rectal (C19.9, C20.9, and C21.8). On the basis of established guidelines and 10 available MSI markers (34), cases were classified as MSI-stable if 0% of loci were unstable, MSI-low if less than 30% of loci were unstable, and MSI-high if 30% or more of loci were unstable, with unequivocal results for at least 4 markers required to characterize MSI status.

### Statistical analyses

Cox proportional hazards regression models were used to calculate HRs and 95% CIs for the association between each SNP and CRC survival. Regression models assumed a dominant mode of inheritance; the number of events was not sufficient to evaluate unrestricted or log-additive models. Cox models included adjustment for sex, age at diagnosis, and self-reported White/non-White race; models additionally including the stage of disease at diagnosis were also run. In exploratory analyses, models were restricted to Caucasians ( $n = 381$ ). Regression models were also run with all-cause mortality as an outcome. Results were considered statistically significant if the 2-sided value of  $P < 0.05$ .

To address the issue of conducting multiple tests within each gene, we applied the false discovery rate (FDR) control method of Benjamini and Hochberg (35, 36). The control of the FDR using the Benjamini and Hochberg (B&H) method takes a decidedly different approach from the more conservative family-wise error rate (FWER) methods, including the Bonferroni correction, balancing protection against false inference with the ability to detect true associations. The B&H method is a step-up method that requires listing the  $P$  values calculated from regression analyses in descending order from highest to lowest (i.e., values closer to 0 listed first). Once a FDR level has been predetermined, the B&H method takes into account both the total number of tests done (i.e., number of SNPs tested) and the  $P$  values calculated for each test from regression models to calculate an adjusted  $P$  value for each test (i.e., each SNP). These adjusted  $P$  values are compared with the  $P$  values calculated directly from regression models, and a list of noteworthy SNPs at the FDR level chosen is identified. Instead of protecting against any type I error (i.e., one or more false positives), the B&H method allows for false positive results in the process of discovering true positives and guarantees that under repeated use, the long-run average of false positives will fall at or below some prespecified FDR level.

For example, if a FDR level (i.e., 25%) is chosen, the following equation is applied to each of the sequentially listed  $P$  values in a given gene, beginning from the least to most extreme (i.e., beginning at the bottom of the list of  $P$  values):  $\text{FDR} \times (P \text{ value order} / \text{total } P \text{ values})$ . At an FDR of 25%, the Benjamini-adjusted  $P$  value for the sixth ordered SNP of a list of 20 SNP  $P$  values in a given gene would be:  $0.25 \times (6/20) = 0.08$ . If the  $P$  value for the  $n^{\text{th}}$  ordered value falls below the Benjamini-adjusted  $P$  value, all SNPs with  $P$  values equal to or less than that ordered value are considered noteworthy. Returning to the previous example, if the  $P$

value (calculated from Cox regression) for the sixth ordered SNP were less than 0.08, the first 6  $P$  values (i.e., first 6 SNPs) would all be considered noteworthy at the FDR 25% level. Of these, we would expect that one quarter (less than 2) would be false positive but that the remaining three quarters (at least 4) are true positives.

This FDR method controls the number of false positives so that we have confidence that a certain percentage of the positive results reported are in fact true positives, recognizing at the same time that a certain percentage are false positives. We generated a list of noteworthy SNPs at both the FDR 50% and FDR 25% levels for the 5 genes investigated.

### Results

After an average of 6.5 years (SD = 3.1 years) of follow-up after CRC diagnosis, 151 deaths from any cause were observed. Three quarters of the deaths among patients were due to CRC ( $n = 115$ ). Patients' ages at diagnosis ranged from 23 to 74, with approximately 10% of patients under the age of 40. A slightly larger proportion of deceased patients had microsatellite stable tumors and tumors located in the distal colon. As expected, patients diagnosed with localized tumors had much better overall survival compared with patients with advanced disease, with more than 30% of deceased patients being diagnosed with advanced disease, as compared with only 5% of patients who remained alive at the end of study follow-up (Table 1).

Genetic variation in both *PTGS-1* (COX-1) and *IκBκβ* was associated with prognosis of patients with CRC. These 2 genes had more SNPs with values of  $P < 0.05$  than expected by chance (more than 1 SNP for every 20 tested, detected as statistically significant). In addition, of the 5 genes tested, only *PTGS-1* and *IκBκβ* had SNPs that were noteworthy. All SNPs noteworthy at the FDR 50% level are reported in Tables 2 and 3; SNPs noteworthy at the FDR 25% level are denoted in italics. The other 3 genes investigated did not include noteworthy SNPs; for illustrative purposes,  $P$  values calculated from Cox regression models and B&H-adjusted  $P$  values (at the FDR 50% level) for these 3 genes are presented in Supplementary Tables.

Four of the 17 SNPs in *PTGS-1* were statistically significantly associated with CRC-specific mortality. The presence of the minor allele conferred an approximately 1.5 to 2 times greater risk of CRC mortality compared with the wild-type for 3 of the SNPs (rs10306155: G>A intron 2, rs4836885: A>G intron 8, L237M: C>A exon 7). In contrast, patients with the minor allele for rs1213266 (G>A intron 9) had approximately 50% lower mortality compared with wild-type patients (HR = 0.48; 95% CI, 0.25–0.93; Table 2). Correction for multiple testing confirmed that genetic variation in *PTGS-1* was associated with CRC survival, with 6 SNPs, including all SNPs noted above with value of  $P < 0.05$ , were noteworthy at the FDR 25% level; the expectation is that one quarter of these SNPs (less than 2) are false positives but that the remaining 3 quarters (at least 4) may in fact be associated with CRC survival.

**Table 1.** Characteristics of CRC cases, stratified on vital status<sup>a</sup>

	<b>Total CRC Cases (n = 426)</b>	<b>Deceased (n = 151)</b>	<b>Alive (n = 275)</b>
	<b>N (%)</b>	<b>N (%)</b>	<b>N (%)</b>
Age, y			
<50	203 (47.7)	57 (37.8)	146 (53.1)
50–59.9	86 (20.2)	29 (19.2)	57 (20.8)
60–69.9	94 (22.1)	39 (25.8)	55 (20.0)
≥70	43 (10.1)	26 (17.2)	17 (6.2)
Sex			
Female	198 (46.5)	68 (45.0)	130 (47.3)
Male	228 (53.5)	83 (55.0)	145 (52.7)
Race			
Caucasian	381 (89.4)	136 (90.1)	245 (89.1)
Non-Caucasian	45 (10.6)	15 (9.9)	30 (10.9)
Screening Endoscopy <sup>b</sup>			
No	395 (92.7)	140 (92.7)	255 (92.7)
Yes	31 (7.3)	11 (7.3)	20 (7.3)
History of Polyps			
No	231 (54.2)	82 (54.3)	149 (54.2)
Yes	192 (45.1)	67 (44.4)	125 (45.5)
MSI status <sup>c</sup>			
Stable	196 (72.9)	78 (75.7)	118 (71.1)
Low	36 (13.4)	15 (14.6)	21 (12.7)
High	37 (13.8)	10 (9.7)	27 (16.3)
Tumor stage			
Localized	146 (34.5)	30 (20.1)	116 (42.3)
Regional	216 (51.1)	72 (48.3)	144 (52.6)
Distant	61 (14.4)	47 (31.5)	14 (5.1)
Site of tumor			
Proximal	123 (28.9)	40 (26.5)	97 (35.3)
Distal	137 (32.2)	50 (33.1)	73 (26.6)
Rectal	158 (37.1)	59 (39.1)	99 (36.0)

<sup>a</sup>Vital status is defined as the vital status for each CRC patient at their last date of follow-up, with 35% of patients with CRC deceased during the course of follow-up and 65% alive at last date of contact.

<sup>b</sup>Endoscopy: sigmoidoscopy or colonoscopy received at least 2 years prior to CRC diagnosis.

<sup>c</sup>MSI status of tumors was available for approximately 63% of patients. Percentages reported are out of the total cases with MSI status available.

Two of the 9 SNPs in *IκBKβ* were statistically significantly associated with CRC mortality. Patients with the minor allele for rs11986055 (A > C intron 19) experienced less than half the mortality due to CRC compared with wild-type patients (HR = 0.39; 95% CI, 0.14–1.00; Table 3). Estimates for R524Q were imprecise because only one patient was observed to carry the minor allele. Correction for multiple testing also indicated that genetic variation in *IκBKβ* was associated with CRC

survival, with 2 SNPs in *IκBKβ* noteworthy at the FDR 25% level.

When we restricted analyses to Caucasians only ( $n = 381$ ), we obtained similar results to those reported here. For both *PTGS-1* and *IκBKβ*, all SNPs noteworthy when investigating CRC survival, except one, were also noteworthy when considering the outcome of death from any cause among patients. Effect estimates for the association between these SNPs and all-cause mortality were similar to those specific to CRC. For example, of the 4 SNPs in *PTGS-1* that were statistically significantly associated with CRC-specific mortality, 3 were also statistically significantly associated with all-cause mortality (rs10306155: G>A intron 2, rs4836885: A>G intron 8, L237M: C>A exon 7; Table 2).

Adjustment for stage of disease at diagnosis attenuated the statistical significance of the associations for 3 of the SNPs in *PTGS-1* (rs10306155: G>A intron 2, rs4836885: A>G intron 8, L237M: C > A exon 7), although 2 of these SNPs, rs10306155 (G>A intron 2) and L237M (C > A exon 7), remained marginally associated with CRC-specific mortality (HR = 1.48; 95% CI, 0.96–2.28; HR = 1.77; 95% CI, 0.91–3.45, respectively). For these SNPs, patients with the wild-type genotype were statistically significantly less likely than patients with the minor allele to present with advanced stage of disease at diagnosis. For both rs10306155 (G>A intron 2) and rs4836885 (A>G intron 8), approximately 13% of patients with the wild-type genotype presented with advanced disease, compared with approximately 19% of patients with the minor allele. For L237M, 14% of patients with the LL genotype presented with advanced tumors compared with 29% of patients with either the LM or MM genotype.

Adjustment for other tumor characteristics, including MSI status and tumor subsite, did not alter reported effect estimates, and the distribution of these tumor characteristics was similar between cases with and without the minor allele for all except L237M. Although approximately 36% and 30% of patients with the LL genotype presented with rectal and distal tumors, respectively, only about 13% of patients with either the LM or MM genotype presented with distal tumors, and 50% presented with rectal tumors.

## Discussion

This investigation is one of the first to explore the relationship between inherited genetic polymorphisms and CRC survival. Genetic variation in both *PTGS-1* (*COX-1*) and *IκBKβ* was associated with an altered risk of mortality from CRC. Our confidence in these results is strengthened by the fact that specific polymorphisms in *PTGS-1* and *IκBKβ* showed consistent statistical evidence of an association with CRC survival. Both genes had more SNPs with statistically significant associations than would be expected by chance; each gene had multiple SNPs that were noteworthy using the B&H FDR control method; and all of the statistically significant SNPs in both *PTGS-1* and *IκBKβ* were also noteworthy SNPs at the FDR 25% level.

**Table 2.** Associations between *PTGS-1* polymorphisms<sup>a</sup>, CRC mortality, and all-cause mortality

Common name	dbSNP ID	MAF (%)	CRC mortality				All-cause mortality			
			Alive/ censored	CRC deaths	HR (95% CI) for CRC mortality	<i>P</i>	Alive	Death from any cause	HR (95% CI) for all-cause mortality	<i>P</i>
G>A intron 9	rs1213266	GG	254	103	1.00	—	226	131	1.00	—
		AG/AA	58	11	0.48 (0.25–0.93)	0.02	49	20	0.71 (0.43–1.15)	0.16
G>A intron 2	rs10306155 <sup>b,c</sup>	GG	242	80	1.00	—	215	107	1.00	—
		AG/AA	70	34	1.62 (1.06–2.49)	0.03	60	44	1.63 (1.13–2.36)	< 0.01
A>G intron 8	rs4836885 <sup>b,d</sup>	AA	231	77	1.00	—	205	103	1.00	—
		AG/GG	76	37	1.55 (1.02–2.34)	0.04	67	46	1.47 (1.02–2.12)	0.04
C>A exon 7	L237M	CC	298	104	1.00	—	263	139	1.00	—
		CA/AA	14	10	2.09 (1.07–4.06)	0.05	12	12	2.08 (1.14–3.82)	0.02
G>A intron 8	rs9299280 <sup>c,d</sup>	GG	232	77	1.00	—	205	104	1.00	—
		AG/AA	80	37	1.48 (0.98–2.25)	0.07	70	47	1.44 (1.00–2.07)	0.05
A>G intron 8	rs6478565 <sup>e</sup>	AA	207	68	1.00	—	183	92	1.00	—
		AG/GG	105	46	1.44 (0.97–2.13)	0.08	92	59	1.37 (0.97–1.94)	0.07
A>G intron 8	rs10306163 <sup>f</sup>	AA	192	64	1.00	—	170	86	1.00	—
		AG/GG	118	50	1.33 (0.89–1.97)	0.16	103	65	1.29 (0.92–1.82)	0.14
G>C intron 7	rs4273915 <sup>e</sup>	GG	210	73	1.00	—	186	97	1.00	—
		GC/CC	102	41	1.30 (0.87–1.95)	0.20	89	54	1.29 (0.91–1.83)	0.15
A>G intron 9	rs12551233	AA	257	98	1.00	—	225	130	1.00	—
		AG/GG	55	16	0.72 (0.41–1.27)	0.24	50	21	0.68 (0.41–1.12)	0.13
A>G intron 7	rs3842798 <sup>f</sup>	AA	196	68	1.00	—	174	90	1.00	—
		AG/GG	116	46	1.23 (0.83–1.84)	0.30	101	61	1.24 (0.88–1.75)	0.23
G>A intron 2	rs12353214	GG	250	86	1.00	—	223	113	1.00	—
		AG/AA	62	28	1.26 (0.80–1.98)	0.34	52	38	1.36 (0.92–2.00)	0.12
C>A exon 2	P17L	CC	275	97	1.00	—	243	129	1.00	—
		AC/AA	55	16	1.33 (0.76–2.34)	0.34	30	20	1.22 (0.73–2.03)	0.45 <sup>g</sup>

NOTE: Results in italics were noteworthy at the FDR 25% level (6 SNPs for CRC-specific and 5 SNPs for all-cause mortality).

Results in table above are adjusted for age, sex, and reported race at enrollment.

MAF were calculated among unaffected siblings of cases.

<sup>a</sup>The SNPs were 'noteworthy' at an FDR 50% level when investigating both CRC-specific and all-cause mortality unless otherwise noted.

<sup>b</sup>SNPs are in high LD ( $r^2 = 0.93$ ).

<sup>c</sup>SNPs are in high LD ( $r^2 = 0.87$ ).

<sup>d</sup>SNPs are in high LD ( $r^2 = 0.95$ ).

<sup>e</sup>SNPs are in high LD ( $r^2 = 0.91$ ).

<sup>f</sup>SNPs are in high LD ( $r^2 = 0.95$ ).

<sup>g</sup>SNP was not 'noteworthy' at the FRD 50% level for all-cause mortality.

**Table 3.** Associations between *IκBKβ* polymorphisms<sup>a</sup>, CRC mortality, and all-cause mortality

Common name	dbSNP ID	MAF (%)	CRC mortality				All-cause mortality			
			Alive/ censored	CRC deaths	HR (95% CI) for CRC mortality	<i>P</i>	Alive	Death from any cause	HR (95% CI) for all-cause mortality	<i>P</i>
A>C intron 19	rs11986055									
	AA		281	109	1.00	—	247	142	1.00	—
	AC/CC	9.5	31	5	0.39 (0.14–1.00)	0.04	28	8	0.44 (0.19–1.02)	0.06
G>A exon 15	R526Q									
	GG		312	113	1.00	—	275	150	1.00	—
	AG/AA	0.2	0	1	23.3 (2.62–207.7)	0.04	0	1	50.03 (5.7–437.2)	<0.01
C>T	rs6474387									
	CC		263	101	1.00	—	230	134	1.00	—
	CT/TT	15.0	48	12	0.57 (0.28–1.13)	0.08	44	16	0.57 (0.32–1.04)	0.07
T>A intron 1	rs3747811									
	TT		84	39	1.00	—	74	49	1.00	—
	AT/AA	69.8	228	75	0.69 (0.46–1.04)	0.09	201	102	0.79 (0.55–1.14)	0.21
G>A intron 19	rs10958713									
	GG		138	54	1.00	—	121	71	1.00	—
	AG/AA	55.9	173	60	0.80 (0.54–1.18)	0.26	153	80	0.86 (0.62–1.21)	0.40 <sup>b</sup>
A>G intron 5	rs9694958									
	AA		264	101	1.00	—	233	132	1.00	—
	AG/GG	14.6	48	13	0.72 (0.39–1.33)	0.27	42	19	0.76 (0.45–1.27)	0.29
G>A intron 5	rs2272733									
	GG		247	94	1.00	—	217	124	1.00	—
	AG/AA	19.6	65	20	0.77 (0.45–1.29)	0.30	58	27	0.76 (0.48–1.19)	0.23

NOTE: Results in italics were also noteworthy at the FDR 25% level (2 SNPs for CRC-specific and 3 SNPs for all-cause mortality). Results in table above are adjusted for age, sex, and reported race at enrollment.

MAF were calculated among unaffected siblings of cases.

<sup>a</sup>The SNPs were 'noteworthy' at an FDR 50% level when investigating both CRC-specific and all-cause mortality unless otherwise noted.

<sup>b</sup>SNP was not 'noteworthy' at the FDR 50% level for all-cause mortality.

The majority of the SNPs identified have not been thoroughly characterized with respect to function, but at least 3 of the polymorphisms identified result in nonsynonymous coding amino acid changes. The presence of the minor allele (A allele) in L237M (rs5789) in *PTGS-1* results in a leucine to methionine change at amino acid position 237; the presence of the minor allele (A allele) in P17L (rs3842787) in *PTGS-1* results in a proline to leucine change at amino acid position 17; and the minor allele (A allele) in R524Q (rs2272736) of *IκBKβ* results in an arginine to glutamine change. The L237M polymorphism has been characterized previously as significantly altering protein expression levels of COX-1 (37, 38). Future studies are warranted to determine if the other nonsynonymous coding change polymorphisms may result in functional changes in protein expression levels.

Multiple SNPs in *PTGS-1* were observed to be in high LD ( $r^2 > 0.80$ ): rs10306155 and rs4836885 ( $r^2 = 0.93$ ); rs10306155 and rs9299280 ( $r^2 = 0.87$ ); rs4836885 and rs9299280 ( $r^2 = 0.95$ ); rs6478565 and 4273915 ( $r^2 =$

0.91); rs10306163 and rs3842798 ( $r^2 = 0.95$ ). These SNPs can be grouped into 3 LD blocks in *PTGS-1*: bin 1 (rs10306155: G>A intron 2, rs4836885: A>G intron 8, and rs9299280: G>A intron 8), bin 2 (rs10306163: A>G intron 8, rs3842798: A>G exon 7), and bin 4 (rs6478565: A>G intron 8, rs4273915: G>C intron 7). Although this may represent some redundancy in the information for any of these given SNPs, at least 3 distinct SNPs with values of  $P < 0.05$  and 4 SNPs noteworthy at the FDR 25% level would remain if only one SNP from each of these bins were included in our analyses; the inference that genetic variation in *PTGS-1* (COX-1) is associated with CRC mortality would be unchanged. In addition, the observation of multiple noteworthy SNPs within one LD block provides stronger evidence that these particular regions of the prostaglandin synthase 1 gene may be associated with CRC prognosis.

It is biologically plausible that these genes, which influence inflammation, are involved in CRC survival. Prostaglandin synthase 2 (COX-2) expression has been linked to

CRC recurrence and to specific processes such as angiogenesis that are crucial for tumor progression(39, 40). Prostaglandin synthase 1 (COX-1), which is constitutively expressed in the colon, has not been as thoroughly investigated, despite synthesizing the same downstream prostanooids and having a demonstrated role in tumorigenesis (41, 42). COX-1 is involved in maintaining the colonic mucosa and vasculature (43, 44); alterations in the cumulative level of prostaglandins resulting from genetic variation in *PTGS-1* could interrupt these functions and contribute to cancer progression by altering the ability of tumor to promote angiogenesis and cellular extravasation and invasion.

*IκBκβ* has previously been identified as a crucial link between inflammatory processes and carcinogenesis in laboratory studies.(45, 46) This role in carcinogenesis is likely due to the inhibition of NFκB transcriptional activity by *IκBκβ* and the resulting resolution of NFκB-mediated inflammation in cells(47, 48). In addition, crucial downstream targets of the NFκB transcription factor include the prostaglandin synthases (19, 22); disruptions in the regulation of NFκB through variation in *IκBκβ* could lead to altered COX-1 and COX-2 expression, resulting in variation in prostanoid production that could contribute to cancer progression.

Prior genome-wide scans investigating CRC incidence have not identified these genes as loci related to CRC initiation. However, investigation of the association between the top variants identified in scans of CRC risk with respect to the outcome of CRC survival has yielded null results (49). CRC incidence and CRC progression and prognosis, although related, are independent outcomes, and we expect that variants identified as important for disease progression may not be equally important for disease initiation. Inflammation is known to be important for initiation, but an important role also exists for inflammation in the regulation of cellular adhesion, disintegration of the extracellular matrix, and angiogenesis, which all affect tumor invasion and metastatic potential. Our results are novel, and further studies, particularly genome-wide scans, investigating the role of genetic variation in CRC prognosis may in fact identify new loci that were not identified in scans related to disease incidence.

The associations observed here may be due, in part, to an association between variation in the investigated genes and the stage at which CRC is diagnosed in patients. Inherited genetic variation is a lifelong exposure, such that polymorphisms in a given individual may alter the rate at which disease develops and progresses, resulting in CRC diagnosis at a different stage of disease. If genetic variation alters survival after a diagnosis of CRC because it alters the stage at which the tumor is diagnosed, then stage may be considered part of the "causal pathway" between genetic variation and CRC survival. This is consistent with our observations, in that adjustment for stage attenuated the magnitude of observed associations for certain SNPs in *PTGS-1*, and patients with minor alleles for these SNPs were more likely to present with advanced stage of disease at diagnosis.

The B&H method, rather than asking whether any individual test result is a false positive, is designed instead to answer the question of whether any of the positive test results generated may in fact warrant further investigation. Use of this method allowed us to take a gene-by-gene analysis approach, answering the question of whether any variation in each of the selected proinflammatory pathway genes, not just in particular SNPs, was associated with mortality after a diagnosis of CRC. The control of the FDR often has increased statistical power to detect true positives and may arguably be a more suitable method than the more conservative Bonferroni test for studies seeking to generate potential hypotheses for replication in future studies (36). Utilizing a standard FDR level has been suggested to be a potentially more useful method for allowing a uniform comparison of genetic epidemiology studies (50).

Additional study strengths include accurate exposure measurement and complete and standardized outcome follow-up for all study participants. The potential for population stratification was examined by restriction of analyses to Caucasian patients only, with no differences in associations observed. The average time between diagnosis and study enrollment for cases in the Seattle Colon CFR was 8 months (95% CI, 3–13), such that our study did not suffer from long lag times between diagnosis and enrollment that can result in patient loss, particularly loss of patients with more advanced stages of disease, and limit generalizability of results.

This is one of the first investigations of inherited genetic variation and CRC survival; additional studies with larger sample sizes and more ethnically diverse study populations are required to confirm our findings and to further characterize the specific nature of the associations between the identified genes and patient survival. Future studies should also include more detailed treatment information. We were only able to consider first-line treatment data in our analysis; although these data did not alter observed associations, the examination of more detailed treatment information could shed light on potential interactions between inherited genetic variation and treatment responses. Finally, patients originated from a population-based cancer registry, but the design of the parent genetic association studies required that each patient with CRC had to have a sibling that was not affected by CRC to participate. The minor allele frequencies observed in this study population were higher than would be expected in a population that was not enriched with a first-degree family history of CRC. Although the direction of the potential bias introduced by this selection is difficult to predict, future studies should be conducted in true population-based samples to maximize generalizability.

Very little is known about the role of genetic variation in altering patient survival after a diagnosis of CRC. Our findings suggest that variation in genes involved in crucial inflammatory pathways may be important for disease prognosis. This study begins to shed light on specific proinflammatory genes that should be investigated further; both

*PTGS-1* (COX-1) and *IκBκβ* should be top priority genes for inclusion in future studies of CRC outcomes.

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

### Acknowledgments

The authors thank Ms. Allyson Templeton for her contributions to establishing the Seattle Colon CFR study population.

### Grant Support

This work was supported by grants from the National Cancer Institute, the NIH Grants T32 CA09168, R03 CA137791, and U24 CA074794.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 2, 2011; revised August 12, 2011; accepted September 12, 2011; published OnlineFirst October 5, 2011.

### References

1. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. *Gastroenterology* 2010;138:2101–14.e5.
2. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. *Nat Rev Cancer* 2006;6:130–40.
3. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. *Contrib Microbiol* 2006;13:118–37.
4. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. *Curr Opin Immunol* 2007;19:209–16.
5. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation-mediated promotion of invasion and metastasis. *Cancer Metastasis Rev* 2010;29:243–8.
6. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 2003;348:891–9.
7. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanasa A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. *Gastroenterology* 2006;131:1674–82.
8. Baron JA. Aspirin and NSAIDs for the prevention of colorectal cancer. *Recent Results Cancer Res* 2009;181:223–9.
9. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. *JAMA* 2009;302:649–58.
10. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. *Gut* 2011;60:491–8.
11. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *Lancet* 2010;376:1741–50.
12. Chan TA. Prostaglandins and the colon cancer connection. *Trends Mol Med* 2006;12:240–4.
13. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. *Carcinogenesis* 2009;30:377–86.
14. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. *Gastroenterology* 2005;128:1445–61.
15. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. *Cancer Lett* 2004;215:1–20.
16. Buchanan FG, Chang W, Sheng H, Shao J, Morrow JD, DuBois RN. Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. *Gastroenterology* 2004;127:1391–400.
17. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. *Clin Cancer Res* 2000;6:4064–8.
18. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. *J Biol Chem* 2001;276:18075–81.
19. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. *Cell Mol Immunol* 2009;6:327–34.
20. Horst D, Budczies J, Brabletz T, Kirchner T, Hlubek F. Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. *Cancer* 2009;115:4946–58.
21. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 2005;5:749–59.
22. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. *Int J Biochem Cell Biol* 2006;38:1654–61.
23. Dutta J, Fan Y, Gupta N, Fan G, Gelinias C. Current insights into the regulation of programmed cell death by NF-kappaB. *Oncogene* 2006;25:6800–16.
24. Fan Y, Dutta J, Gupta N, Fan G, Gelinias C. Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. *Adv Exp Med Biol* 2008;615:223–50.
25. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, Gonzalez-Aguilera JJ, Fernandez-Peralta AM. Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. *Cancer Causes Control* 2009;20:1421–9.
26. Andersen V, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in NFKB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. *BMC Cancer* 2010;10:484.
27. Curtin K, Wolff RK, Herrick JS, Abo R, Slattery ML. Exploring multilocus associations of inflammation genes and colorectal cancer risk using hapConstructor. *BMC Med Genet* 2010;11:170.
28. Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, et al. Polymorphisms in PTGS1 (= COX-1) and risk of colorectal polyps. *Cancer Epidemiol Biomarkers Prev* 2004;13:889–93.
29. Zhu W, Wei BB, Shan X, Liu P. -765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. *Mol Biol Rep* 2010;37:277–88.
30. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16:2331–43.
31. Levine AJ, Figueiredo JC, Lee W, Conti DV, Kennedy K, Duggan DJ, et al. A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 2010;19:1812–21.
32. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. *Am J Epidemiol* 1993;137:235–41.
33. Stampfer M, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index. *Am J Epidemiol* 1984;119:837–9.
34. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248–57.
35. Benjamini Ya Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Royal Stat Soc Ser B (Methodological)* 1995;57:289–300.

36. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. *Behav Brain Res* 2001;125:279–84.
37. Lee CR, Bottone FG, Jr., Krahn JM, Li L, Mohrenweiser HW, Cook ME, et al. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). *Pharmacogenet Genomics* 2007;17:145–60.
38. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. *Hum Mutat* 2002;20:409–10.
39. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. *Br J Cancer* 2000;83:324–8.
40. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. *Cancer Res* 2003;63:2330–4.
41. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. *Annu Rev Med* 2007;58:239–52.
42. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. *Cancer Res* 2000;60:4705–8.
43. Smith WL. The eicosanoids and their biochemical mechanisms of action. *Biochem J* 1989;259:315–24.
44. Takafuji VA, Evans A, Lynch KR, Roche JK. PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer. *Prostaglandins Leukot Essent Fatty Acids* 2002;66:71–81.
45. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 2004;118:285–96.
46. Karin M. The I kappa B kinase - a bridge between inflammation and cancer. *Cell Res* 2008;18:334–42.
47. Lawrence T, Bebiec M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. *Nature* 2005;434:1138–43.
48. Schmid JA, Birbach A. I kappa B kinase beta (IKKbeta/IKK2/IKBKB)—a key molecule in signaling to the transcription factor NF-kappaB. *Cytokine Growth Factor Rev* 2008;19:157–65.
49. Tenesa A, Theodoratou E, Din FV, Farrington SM, Cetnarskyj R, Barnetson RA, et al. Ten common genetic variants associated with colorectal cancer risk are not associated with survival after diagnosis. *Clin Cancer Res* 2010;16:3754–9.
50. van den Oord EJ. Controlling false discoveries in genetic studies. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B:637–44.

# Clinical Cancer Research

## Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival

Anna E. Coghill, Polly A. Newcomb, Elizabeth M. Poole, et al.

*Clin Cancer Res* 2011;17:7139-7147. Published OnlineFirst October 5, 2011.

<b>Updated version</b>	Access the most recent version of this article at: doi: <a href="https://doi.org/10.1158/1078-0432.CCR-11-1134">10.1158/1078-0432.CCR-11-1134</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2011/09/28/1078-0432.CCR-11-1134.DC1">http://clincancerres.aacrjournals.org/content/suppl/2011/09/28/1078-0432.CCR-11-1134.DC1</a>

<b>Cited articles</b>	This article cites 50 articles, 11 of which you can access for free at: <a href="http://clincancerres.aacrjournals.org/content/17/22/7139.full#ref-list-1">http://clincancerres.aacrjournals.org/content/17/22/7139.full#ref-list-1</a>
-----------------------	--

<b>Citing articles</b>	This article has been cited by 1 HighWire-hosted articles. Access the articles at: <a href="http://clincancerres.aacrjournals.org/content/17/22/7139.full#related-urls">http://clincancerres.aacrjournals.org/content/17/22/7139.full#related-urls</a>
------------------------	---

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
----------------------	--

<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
-----------------------------------	--

<b>Permissions</b>	To request permission to re-use all or part of this article, use this link <a href="http://clincancerres.aacrjournals.org/content/17/22/7139">http://clincancerres.aacrjournals.org/content/17/22/7139</a> . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.
--------------------	--